Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
usx:exel sgx:b10 Blog PostFarallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
usx:exel Blog PostExelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC
usx:bmy usx:exel Blog Post